Kira Biotech Raises A$20M in Series A Funding

kira biotechKira Biotech, a Brisbane, Australia-based immunology company, secured A$20m in Series A funding.

The round was led by OneVentures, IP Group and the Advance Queensland Business Development Fund.

The company intencds to use the funds to advance its lead candidate KB312 through phase 1 human studies.

Led by Dr Dan Baker, founding CEO, Kira Biotech is a biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders, such as rheumatoid arthritis, systemic lupus erythematosus and type 1 diabete.
KB312 is an antibody with a novel target that is common to many immune system disorders and is key to restoration or induction of immune tolerance. The company is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by Dr Baker.
The research program is based on decades of research led by the late Professor Derek Hart and Associate Professor Georgina Clark.



Join the discussion